Zobrazeno 1 - 10
of 1 350
pro vyhledávání: ''
Autor:
Federico Innocenti, Spinel Karas
Publikováno v:
JCO Oncology Practice. 18:270-277
Irinotecan is an anticancer agent widely used for the treatment of solid tumors, including colorectal and pancreatic cancers. Severe neutropenia and diarrhea are common dose-limiting toxicities of irinotecan-based therapy, and UGT1A1 polymorphisms ar
Autor:
Caicun Zhou, Suresh S. Ramalingam, Ki Hyeong Lee, Kazuhiko Nakagawa, Natasha B. Leighl, Astrid McKeown, Naoyuki Nogami, Thanyanan Reungwetwattana, Johan Vansteenkiste, Eun Kyung Cho, Alessandro Bertolini, Andrew P. Brown, Byoung Chul Cho, Manuel Cobo, Rachel Hodge, Isamu Okamoto, Sabine Bohnet, Yuri Rukazenkov
Publikováno v:
Journal of Clinical Oncology. 36:3290-3297
Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated advanced non–small-cell lung cancer from the phase III FLAURA study. Pa
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
Sarina Anne Piha-Paul, Shari Thomas, Hope S. Rugo, Emilie M.J. van Brummelen, Andrea Varga, Reshma A. Rangwala, Sanatan Saraf, Jean-Sebastien Frenel, Carlos Gomez-Roca, Christophe Le Tourneau, Patrick A. Ott, Bert H. O'Neil
Publikováno v:
Journal of Clinical Oncology. 35:4035-4041
Purpose The KEYNOTE-028 trial ( ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy of pembrolizumab in 20 programmed death ligand 1–positive, advanced solid tumor cohorts. Here, we present the results from th
Autor:
Li Man, Caijun Yuan, Lizhong Zhou, Jing Shi, Xiujuan Qu, Feng Jin, Fugang Wen, Xiuna Zhang, Ying Luo, Jinglei Qu, Zan Teng, Bo Jin, Tao Sun, Lingyun Zhang, Jian Zhang, Xiuhua Jin, Ping Yu, Mingfang Zhao, Tiejun Chen, Jingyan Wang, Jun Wang, Yuyang Dong, Xiaodong Xie, Ying Chen, Jing Liu, Lingyu Fu, Jingdong Zhang, Yuee Teng, Zhenghua Wang, Yunpeng Liu, Zhitu Zhu, Yuzhi An
Publikováno v:
Journal of Clinical Oncology. 35:3558-3565
Purpose We examined the efficacy and safety of thalidomide (THD) for the prevention of delayed nausea and vomiting in patients who received highly emetogenic chemotherapy (HEC). Patients and Methods In a randomized, double-blind, active-controlled, p
Autor:
Elizabeth Fox, Yael P. Mosse, Charles G. Minard, Megan S. Lim, Susan M. Blaney, Peter C. Adamson, Brenda J. Weigel, Keith D. Wilner, Stephan D. Voss, Delphine Rolland
Publikováno v:
Journal of Clinical Oncology. 35:3215-3221
Purpose Fusions involving the ALK gene are the predominant genetic lesion underlying pediatric anaplastic large cell lymphomas (ALCL) and inflammatory myofibroblastic tumors (IMTs). We assessed the activity of the ALK inhibitor crizotinib in patients
Autor:
Franco Nolè, Silke Gillessen, Yohann Loriot, Alejo Rodriguez-Vida, Raymond S. McDermott, Fred Saad, Bertrand F. Tombal, T. Roumeguere, Gedske Daugaard, Anouk Neven, Beatrice Fournier, Ananya Choudhury, Enrique Gallardo Diaz
Publikováno v:
Journal of Clinical Oncology. 39:5002-5002
5002 Background: The randomized phase III EORTC-1333-GUCG (NCT02194842) trial compares enzalutamide vs. a combination of Radium 223 and enzalutamide in asymptomatic or mildly symptomatic metastatic castration resistant prostate cancer (mCRPC) patient
Autor:
Daniel Egle, Christian F. Singer, Barbara Pistilli, Utpal Khambholja, José A. García-Sáenz, Maureen E. Trudeau, Feng Xu, Ron Bose, Daniel Hunt, Carlos H. Barcenas, Manuel Ruiz-Borrego, Adam Brufsky, Dieter Semsek, M. Thirlwell, K. A. Cheong, Johanna Wassermann, Naisargee Shah, Amy Jo Chien, Arlene Chan, Gavin Marx
Publikováno v:
Journal of Clinical Oncology. 39:536-536
536 Background: The primary tolerability concern with neratinib (NERLYNX®; N), an irreversible pan-HER tyrosine kinase inhibitor, is diarrhea. Data from the multi-cohort, open-label, phase 2 CONTROL trial [Barcenas et al. Ann Oncol 2020] demonstrate
Autor:
Silvia Olivari Tilola, Rudolph M. Navari, Erminio Bonizzoni, Eric Roeland, Gary Binder, Rebecca Clark-Snow
Publikováno v:
Journal of Clinical Oncology. 39:12091-12091
12091 Background: The historical standard clinical trial endpoint for preventing chemotherapy-induced nausea and vomiting (CINV) has been assessment of complete response (CR: no emesis and no rescue medication use) over five days. Recent evaluations
Autor:
Alessandro Racioppi, Stefanie Denning, Amy S. Etheridge, Jin Wang, Susan Geyer, Julia C F Quintanilha, Kelli Hammond, Carol Peña, Daniel J. Crona, Federico Innocenti, Sawyer B. Jacobson, Ghassan K. Abou-Alfa
Publikováno v:
Journal of Clinical Oncology. 39:3030-3030
3030 Background: Diarrhea, HFS, and hypertension are common toxicities of sorafenib. No markers are validated to predict patients at risk of these toxicities. This study aimed to identify genetic predictors of sorafenib-induced toxicities. Methods: A